Skip to main content
. Author manuscript; available in PMC: 2022 Feb 12.
Published in final edited form as: J Med Chem. 2021 Jul 16;64(15):11045–11062. doi: 10.1021/acs.jmedchem.1c00439

Figure 3.

Figure 3.

(A) 26f antagonizes AR function in LNCaP prostate cancer cells. LNCaP cells were maintained for 2 d in a charcoal-stripped fetal bovine serum (csFBS)-containing medium. The cells were treated with antagonists, as indicated in the figure, for 20–24 h, RNA was isolated, and expression of AR target gene, FKBP5, was measured and normalized to GAPDH using real-time polymerase chain reaction (PCR). (B) 26f antagonizes AR function in LNCaP prostate cancer cells. LNCaP cells were maintained in a csFBS-containing medium for 2 d. The medium was changed and treated as indicated with 10 μM 26f in the presence of 0.1 nM R1881. Cells were harvested 24 h after treatment, and expression of PSA was measured by real-time PCR and normalized to GAPDH. (C) Enzalutamide (5)-resistant (EnzR) LNCaP cells (MR49F) were plated in 96-well plates in a 1% csFBS-containing medium. Cells were maintained in this medium for 2 days and treated as indicated in the figure. RNA was extracted, and real-time PCR for FKBP5 was performed and normalized to GAPDH expression.